Skip to content

Clinical trials

Lung Diseases, Obstructive trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Lung Diseases, Obstructive Clear all

199 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20002
20021
20034
20041
200511
20061
20072
20085
20097
20106
20116
20127
20135
201414
20159
201613
20176
201811
20197
20206
20215
20229
202314
202410
20255
20265

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed141
Unknown status21
Recruiting11
Terminated10
Active, not recruiting6
Withdrawn6
Not yet recruiting4

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Heart, Lung, and Blood Institute (NHLBI)25
AstraZeneca20
University of Zurich7
University of Michigan5
Novartis Pharmaceuticals4
Royal Brompton & Harefield NHS Foundation Trust4
Assistance Publique - Hôpitaux de Paris3
Columbia University3
Radboud University Medical Center3
Albert Einstein College of Medicine2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Lung Diseases, Obstructive199
Pulmonary Disease, Chronic Obstructive103
Lung Diseases67
Asthma51
Respiratory Tract Diseases47
Bronchial Diseases32
Emphysema16
Immune System Diseases12
Bronchitis, Chronic9
Hypersensitivity9

Trials

Showing 51 to 75 of 199. Each trial links to its page on Pharma Observatory.

99 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.